聚焦超声联合化疗治疗不可切除胰腺癌的概念验证研究
本研究纳入不可切除胰腺癌患者,评估聚焦超声(FUS)联合化疗(白蛋白紫杉醇+吉西他滨)的安全性及初步疗效。预设低、中、高三种FUS强度(1.5、2.0、2.5 kW/cm²),采用1%占空比和3+3方案,共6次联合治疗。结果显示无器械相关不良事件或剂量限制性毒性;9例中7例肿瘤缩小>15%,所有患者CA19-9下降;中强度组全部患者肿瘤缩小>30%、达部分缓解、CA19-9显著下降且生存期更长(p<0.05)。结论认为FUS强度1.5-2.5 kW/cm²联合化疗安全,可用于后续临床试验。
要点
- FUS(1.5-2.5 kW/cm²,1%占空比)联合化疗未出现器械相关不良事件或剂量限制性毒性。
- 中强度组(2.0 kW/cm²)全部患者肿瘤缩小>30%、达部分缓解且CA19-9显著下降。
- 随访CT显示9例中7例肿瘤缩小>15%,所有患者CA19-9立即随访时下降。
关键影像表现/征象
- 立即随访CT和3个月随访CT显示9例中7例肿瘤缩小>15%。
- 中强度组全部患者3个月随访时肿瘤缩小>30%且达部分缓解。
- 所有患者立即随访时CA19-9水平下降,中强度组3个月随访时CA19-9显著下降。
诊断标准与关键数值
- 肿瘤缩小>15%定义为9例中7例达到。
- 中强度组全部患者肿瘤缩小>30%并达部分缓解。
- 中强度组3个月随访CA19-9显著下降且生存期更长(p<0.05)。
临床应用与阅片要点
- 阅片时关注FUS治疗后肿瘤大小变化,尤其>15%和>30%的缩小阈值。
- 结合CA19-9动态变化评估治疗反应,中强度组显示更优的生化反应。
- 报告时应注明FUS参数(强度、占空比)及联合化疗方案,便于后续比较。
局限性
- 每组仅3例,样本量小,为初步概念验证。
- 非随机对照设计,疗效结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the safety and preliminary efficacy of the combined treatment of focused ultrasound (FUS) and chemotherapy (nab-paclitaxel plus gemcitabine, nPac/Gem) for patients with unresectable pancreatic cancer.
METHODS: Patients pathologically diagnosed with unresectable pancreatic cancer were included. Low (Isppa = 1.5 kW/cm2), intermediate (2.0 kW/cm2), and high (2.5 kW/cm2) FUS intensity treatment groups were predefined. A 1% duty cycle and the 3+3 scheme were used. Six combined treatments were performed, and adverse events were assessed. Changes in tumor size and tumor response, CA 19-9 level, and patient-reported outcomes at the immediate follow-up (F/U) and/or at the 3-month F/U and survival were evaluated.
RESULTS: Three participants were enrolled in each intensity group. No adverse device effect or dose-limiting toxicity occurred in any of the participants. Seven of the nine participants experienced a >15% tumor size decrease at the immediate F/U CT and at the 3-month F/U CT. The CA 19-9 level decreased in all of the participants at the immediate F/U. All participants in the intermediate-intensity treatment group showed a > 30% tumor size decrease, partial response, and a significant decrease in the CA 19-9 level at 3-month F/U and longer survival (p < 0.05).
CONCLUSION: FUS with an intensity of 1.5 to 2.5 kW/cm2 was safe in the combined treatment of FUS and nPac/Gem. Considering the results of the change in tumor size, the change in CA 19-9 level, tumor response, and survival, these FUS parameters can be used for subsequent clinical trials.
KEY POINTS: • No adverse device effect or dose-limiting toxicity occurred in any of the participants when focused ultrasound with an intensity of 1.5-2.5 kW/cm2 and a low duty cycle of 1% was combined with chemotherapy. • The intermediate-intensity group showed a >30% tumor size decrease, partial response, and a significant decrease in CA 19-9 in all of the participants at the 3-month follow-up and the longest survival. • Any focused ultrasound setting used in this study could be safe and optimal for subsequent clinical trials.
引用
- Lee, Oh, Lee, et al. Combination of chemotherapy and focused ultrasound for the treatment of unresectable pancreatic cancer: a proof-of-concept study. Eur Radiol. 2022. PMID: 36482217. doi:10.1007/s00330-022-09271-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。